Impact of Biosimilars on Oncology

The FDA has accepted a supplemental new drug application for the combination of darolutamide and androgen deprivation therapy for the treatment of patients with metastatic hormone-sensitive prostate cancer.

In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.

In an interview, Antoni Vilaseca Cabo, MD, discussed the clinical activity of TAR-210 in patients with non-muscle invasive bladder cancer.

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

Denise Yardley, MD, discussed results with ribociclib in patients with early-stage breast cancer with no lymph node involvement who were enrolled in the phase 3 NATALEE trial.

Cesar Rodriguez, MD, discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple myeloma.